Healthcare >> Analyst Interviews >> August 12, 2016

Tackling Specialty Pharma Headwinds by Focusing on Names with Organic Growth and Modest Leverage

Walewicz, Joseph
Joseph Walewicz, CFA, joined Laurentian Bank Securities in August 2014 as a Health Care Analyst. Mr. Walewicz has 14 years of equity research experience with both bank-owned and boutique dealers in both Canada and the U.S. As an Analyst, he has covered a broad range of health care companies, including pharmaceutical, biotechnology, medtech and health care services companies. Mr. Walewicz has been a well-ranked and well-regarded Health Care Analyst, and in 2008 and 2016 was named a top-three stock picker in the Thomson Reuters StarMine awards for the health care sector. In 2014 he returned to the Street from five years in industry, where he served on the board of a private equity-backed, publicly traded health care services company, and served as a business and corporate development executive at two publicly traded biopharmaceutical companies. Mr. Walewicz has a Master of Business Administration from McGill University and is a CFA charterholder. Profile
TWST: What do you cover exactly? 

Mr. Walewicz: I am a Canadian Health Care Analyst at Laurentian Bank Securities. At this point I am covering Canadian specialty